• Explore /
  • Poster
  • / Tumor volume score (TVS), modified recist, and tissue damage score (TDS) as novel methods for assessing response in tenosynovial giant cell tumors (TGCT) treated with pexidartinib: Relationship with patient-reported outcomes (PROs).

Tumor volume score (TVS), modified recist, and tissue damage score (TDS) as novel methods for assessing response in tenosynovial giant cell tumors (TGCT) treated with pexidartinib: Relationship with patient-reported outcomes (PROs).

Abstract Poster

Authors

null

Charles Peterfy

Spire Sciences, Inc., Boca Raton, FL

Charles Peterfy , Xin Ye , Heather Gelhorn , Rebecca M Speck , Peter J. Countryman , Vicki Leigh Keedy , Zev A. Wainberg , Arun S. Singh , Bartosz Chmielowski , Daniel D. Von Hoff , Hani M. Babiker , Vivek Khemka , Gregory Michael Cote , Geoffrey Shapiro , Andrew J. Wagner , John H. Healey , Henry Hsu , Paul S. Lin , Sandra Tong , William D. Tap

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Sarcoma

Track

Sarcoma

Sub Track

Soft Tissue Tumors

Clinical Trial Registration Number

NCT01004861

Citation

J Clin Oncol 35, 2017 (suppl; abstr 11048)

DOI

10.1200/JCO.2017.35.15_suppl.11048

Abstract #

11048

Poster Bd #

371

Abstract Disclosures

Similar Posters

First Author: William D. Tap

Poster

2022 ASCO Gastrointestinal Cancers Symposium

CSF-1R inhibitor, pexidartinib, sensitizes esophageal cancer to PD-1 immune checkpoint blockade in a rat model.

CSF-1R inhibitor, pexidartinib, sensitizes esophageal cancer to PD-1 immune checkpoint blockade in a rat model.

First Author: Michael Paskewicz

First Author: Hans Gelderblom

First Author: Gulam Abbas Manji